Regeneron Pharmaceuticals (REGN)

920.69
-2.65 (-0.29%)
NASDAQ · Last Trade: Nov 20th, 5:42 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close923.34
Open935.80
Bid910.00
Ask931.00
Day's Range916.66 - 948.42
52 Week Range591.52 - 991.73
Volume880,145
Market Cap84.50B
PE Ratio (TTM)20.32
EPS (TTM)45.3
Dividend & Yield3.760 (0.41%)
1 Month Average Volume990,050

Chart

About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More

News & Press Releases

2 Growth Stocks to Buy in November Without Any Hesitationfool.com
Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.
Via The Motley Fool · November 19, 2026
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 19, 2026
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 18, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Combines High Growth Momentum With a Breakout Setupchartmill.com
Via Chartmill · November 18, 2026
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approvalmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference. Chief Financial Officer
Via MarketBeat · November 17, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Frameworkchartmill.com
Via Chartmill · November 3, 2026
S&P 500 Unusual Volume Movers for Nov. 2, 2026chartmill.com
Via Chartmill · November 2, 2026
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 17, 2026
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?fool.com
The stock has climbed more than 40% in one year.
Via The Motley Fool · November 14, 2026
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 12, 2026
S&P 500 Premarket Movers: Gainers and Losers Ahead of the Openchartmill.com
Via Chartmill · November 11, 2026
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%marketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executives said during an investor event. The company said its phase 2b study in patien
Via MarketBeat · November 10, 2026
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitationfool.com
These are among the best the industry has to offer.
Via The Motley Fool · November 8, 2026
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 8, 2026
3 cash-producing stocks walking a fine line
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · November 4, 2026
1 Nasdaq 100 stock on our buy list and 2 facing challenges
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via StockStory · November 2, 2026
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · November 2, 2026
Stock Market Today: Intel’s Worst Day in Four Decades Drags Chips and the Nasdaq to a Rough October Finishchartmill.com
Via Chartmill · November 2, 2026
The top 5 analyst questions from Regeneron’s Q3 earnings call
Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street’s reve...
Via StockStory · November 1, 2026
Regeneron: 3 Key Takeaways for Long-Term Investorsfool.com
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Via The Motley Fool · October 31, 2026
REGN Q3 deep dive: pipeline progress and core brands drive outperformance
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. I...
Via StockStory · October 31, 2026
S&P 500 Top Movers: Gainers and Losers in Today's US Sessionchartmill.com
Via Chartmill · October 30, 2026
Regeneron (REGN) stock trades up, here is why
What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua...
Via StockStory · October 30, 2026
S&P 500 Top Movers: Gainers and Losers in Today's Sessionchartmill.com
Via Chartmill · October 30, 2026
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Callmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,
Via MarketBeat · October 30, 2026